EnteroBiotix Completes Patient Recruitment in Phase 2 TrIuMPH Study

EnteroBiotix Completes Patient Recruitment in Phase 2 TrIuMPH Study

By, Admin 20 November 2024

EnteroBiotix completes patient recruitment in phase 2 TrIuMPH study of EBX-102-02 in irritable bowel syndrome

Overview

EnteroBiotix Limited (EnteroBiotix), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced the completion of recruitment in its phase 2 TrIuMPH (Treating IBS with an Intestinal Microbiota Product for Health) trial assessing the safety, tolerability and efficacy of EBX-102-02, the company’s lead asset, for the treatment of patients with irritable bowel syndrome (IBS).

Phase 2 TrIuMPH Trial

  • The randomised, double-blind, placebo-controlled phase 2 TrIuMPH trial enrolled a total of 122 patients at two sites in the UK. 
  • Patients with confirmed severe IBS-C or IBS-D using Rome IV criteria were randomised 2:1 to receive EBX-102-02 or placebo at two timepoints one week apart and were followed up over a six-week period.
  • The study’s primary objective is to evaluate the safety and tolerability of EBX-102-02 in patients with severe IBS. 
  • Secondary objectives included assessing efficacy, changes in gut microbiome composition and function and relevant biomarkers.

Words from the CEO: EnteroBiotix

Dr James McIlroy MBChB, CEO of EnteroBiotix, commented: ""We are grateful to the trial participants and investigators for helping us advance EBX-102-02 so expeditiously. Reaching this milestone ahead of schedule highlights the dedication of our clinical team and our partnership with the Functional Gut Clinic. The rapid enrolment reflects patient interest and the significant need for innovative IBS therapies that target microbiome imbalances, and we look forward to reporting topline data early next year.”

About the Drug: EBX-102-02

  • EBX-102-02 is a next-generation, full-spectrum drug candidate that contains highly diverse microbial ecosystems and key functional groups that restore and fortify the microbiome. 
  • The drug is presented as an easy to take capsule with demonstrated stability at ambient temperature.

The TrIuMPH Trial

  • TrIuMPH (Treating IBS with an Intestinal Microbiota Product for Health) is a randomised, double-blind, placebo-controlled phase 2 trial designed to evaluate the safety and tolerability of EBX-102-02, EnteroBiotix’s next-generation, full-spectrum microbiome drug candidate, in patients with irritable bowel syndrome (IBS).
  • A total of 122 participants with IBS were recruited to TrIuMPH at two sites. 
  • 62 participants with constipation predominant IBS (IBS-C) and 60 participants with diarrhoea predominant IBS (IBS-D) were dosed with EBX-102-02 or matching placebo and followed up for six weeks.

Irritable Bowel Syndrome

  • Irritable bowel syndrome (IBS) is a chronic relapsing functional gastrointestinal (GI) disorder, with patients experiencing a range of symptoms, such as chronic abdominal pain, cramping, bloating and change in bowel movements – which may include constipation, diarrhoea, or both. 
  • It is estimated that up to 1 in 8 people suffer from IBS type symptoms, and there is approximately an equal split between patients experiencing predominantly constipation (IBS-C) versus diarrhoea (IBS-D) pattern. 
  • In the United States, direct medical costs associated with IBS are estimated to be as high as $10 billion annually, with indirect costs as high as $20 billion (Nellesen et al. 2013).

About the Company: EnteroBiotix

  • EnteroBiotix is a clinical-stage biotechnology company developing therapeutics to treat gastrointestinal and hepatic diseases. 
  • EnteroBiotix’s therapies contain highly diverse ecosystems of microorganisms stabilised using proprietary platform technology and designed to improve gut health by augmenting the gut microbiome.

The FGC

  • The Functional Gut Clinic (FGC) is the UK’s leading independent provider of gastrointestinal physiology testing and diagnostics. 
  • FGC provides both private and NHS services around the UK and is the only independent GI physiology clinic to have Improving Quality in Physiological Services (IQIPS)/United Kingdom Accreditation Services (UKAS) and Care Quality Commission (CQC) accreditation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!